Post-operative atrial fibrillation is a common problem post cardiac surgery with rates exceeding 30%. Atrial fibrillation has multiple adverse effects on cardiac hemodynamics and can lead to hypotension, diminished end organ perfusion and lengthen the stay in ICU. Amiodarone is the medication of choice used for pharmacological cardioversion and can be used with vasoactive medications. Intravenous amiodarone is associated with hypotension and end organ perfusion requiring escalation in vasoactive support. Vernakalant is novel anti-arrhythmic agent approved in Canada for cardioversion of atrial fibrillation that primarily works on atrial channels and has no effect on contractility or vasodilation. Clinical trials have proved good efficacy of Vernakalant in conversion of paroxysmal atrial fibrillation however there is no comparison of Amiodarone to Vernakalant in post-operative cardiac surgery. We plan to perform a clinical trial comparing Vernakalant to amiodarone in post-cardiac surgery patients with a primary outcome of cardioversion at 90 minutes. Secondary outcomes will follow duration of vasoactive medications, days in ICU and economics.

开始日期2024-01-01

申办/合作机构

University of Calgary

NCT04485195 / Recruiting临床4期IIT

RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department

The objective is to compare IV vernakalant to IV procainamide for the ED management of acute AF patients. If vernakalant proves to be more effective, faster, and safer than IV procainamide, this will give clinicians an important alternative for pharmacological cardioversion of acute AF. The investigators propose a pragmatic comparative effectiveness trial entailing an open label, randomized controlled trial at 12 large Canadian EDs. Study subjects will be randomized to 1 of 2 treatment arms: 1) Patients will receive an initial infusion of 3mg/kg of IV vernakalant over 10 minutes, followed by a second dose of 2mg/kg over 10 minutes, if necessary, or 2) Patients will receive a continuous infusion of 15mg/kg of IV procainamide over 60 minutes. The primary aim will be to compare conversion to normal sinus rhythm between the two drugs. The investigators will include stable patients presenting with an episode of acute AF of at least 3 hours duration, where symptoms require urgent management and where immediate cardioversion is a reasonable option. Using the integrated consent model, research assistants will obtain verbal consent from eligible patients.

开始日期2021-06-17

申办/合作机构

Ottawa Hospital Research Institute

NCT03005366 / Completed临床4期IIT

Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide

The main objective of this project is to study the efficacy and the mechanistic value of blocking both atrial specific and atria-preferential dynamics of ionic currents to terminate paroxysmal atrial fibrillation (AF).
The hypothesis is that a drug blocking atrial specific and atria-preferential dynamics of ionic currents (IK,ACh - acetylcholine sensitive K+ current - and INa - inward sodium current - , respectively) will be more effective to terminate paroxysmal AF episodes with fast atrial activation rates, than a classical INa blocker, which will be more effective to terminate AF episodes with slower activation rates.
The investigators will include patients without structural heart disease and short-lasting AF episodes (<48 h.). Double blind and single center study, in which patients will be randomly assigned to a cardioversion group using intravenous flecainide or to an atria-preferential and atrial-specific blockade group using intravenous vernakalant. Patients will be routinely monitored in the electrophysiology room to acquire both 12-lead digitized ECG signals and non-invasive body surface potential mapping. Atrial signals will be extracted from both the multisite body surface and ECG recordings to obtain temporal and spectral parameters, and measure organization and atrial rate in both groups. The results obtained in the clinical setting will be studied in mathematical models to understand their capability to terminate paroxysmal AF. The project expects to provide consistent, reliable and reproducible parameters that will assist clinicians to know what type of paroxysmal AF episodes will be more suitable to effectively terminate, upon administration of drugs with an atrial specific and atria-preferential profile.

开始日期2017-01-01

申办/合作机构

Hospital San Carlos, Madrid

100 项与盐酸维那卡兰相关的临床结果

登录后查看更多信息

100 项与盐酸维那卡兰相关的转化医学

登录后查看更多信息

100 项与盐酸维那卡兰相关的专利（医药）

登录后查看更多信息

208

项与盐酸维那卡兰相关的文献（医药）

2024-02-07·Cardiovascular drugs and therapy

Safety and Effectiveness of Antidysrhythmic Drugs for Pharmacologic Cardioversion of Recent-Onset Atrial Fibrillation: a Systematic Review and Bayesian Network Meta-analysis.

Review

作者: Ian S deSouza ; Pragati Shrestha ; Robert Allen ; Jessica Koos ; Henry Thode

PURPOSE:

The available evidence to determine which antidysrhythmic drug is superior for pharmacologic cardioversion of recent-onset (onset within 48 h) atrial fibrillation (AF) is uncertain. We aimed to identify the safest and most effective agent for pharmacologic cardioversion of recent-onset AF in the emergency department.

METHODS:

We searched MEDLINE, Embase, and Web of Science from inception to February 21, 2023 (PROSPERO: CRD42018083781). Eligible studies were randomized controlled trials that enrolled adult participants with AF ≤ 48 h, compared a guideline-recommended antidysrhythmic drug with another antidysrhythmic drug or a different formulation of the same drug or placebo and reported specific adverse events. The primary outcome was immediate, serious adverse event - cardiac arrest, sustained ventricular tachydysrhythmia, atrial flutter 1:1 atrioventricular conduction, hypotension, and bradycardia. Additional analyses included the outcomes of conversion to sinus rhythm within 4 h and 24 h. We extracted data according to PRISMA-NMA and appraised trials using Cochrane RoB 2. We performed Bayesian network meta-analysis (NMA) using a Markov Chain Monte Carlo method with random-effect model and vague prior distribution to calculate odds ratios with 95% credible intervals. We assessed confidence using CINeMA. We used surface under the cumulative ranking curve (SUCRA) to rank agent(s).

RESULTS:

The systematic review initially identified 5545 studies. Twenty-five studies met eligibility criteria, and 22 studies (n = 3082) provided data for NMA, which demonstrated that vernakalant (SUCRA = 70.9%) is most likely to be safest. Additional effectiveness NMA demonstrated that flecainide (SUCRA = 89.0%) is most likely to be superior for conversion within 4 h (27 studies; n = 2681), and ranolazine-amiodarone IV (SUCRA 93.7%) is most likely to be superior for conversion within 24 h (24 studies; n = 3213). Confidence in the NMA estimates is variable and limited mostly by within-study bias and imprecision.

CONCLUSIONS:

Among guideline-recommended antidysrhythmic drugs, the combination of digoxin IV and amiodarone IV is definitely among the least safe for cardioversion of recent onset AF; flecainide, vernakalant, ibutilide, propafenone, and amiodarone IV are definitely among the most effective for cardioversion within 4 h; flecainide is definitely among the most effective for cardioversion within 24 h. Further, randomized controlled trials with predetermined and strictly defined, hemodynamic adverse event outcomes are recommended.

2023-08-24·Polish archives of internal medicine

Pharmacological cardioversion of atrial fibrillation: practical considerations.

Review

作者: Maciej T Wybraniec ; Zofia Kampka ; Katarzyna Mizia-Stec

The choice between rhythm and rate control strategy represents one of the most intriguing dilemmas in the management of atrial fibrillation (AF). Although the advantage of rhythm over rate control in terms of outcome has not been equivocally proven, the initial management of patients with symptomatic episodes of AF frequently involves an attempt of early cardioversion. As electrical cardioversion (EC) is challenging in terms of fasting status and involvement of anesthesiology team, pharmacological cardioversion (PC) is usually selected as the first step towards rhythm conversion. Proper qualification for PC or EC is similar and should comprise assessment of hemodynamic status, estimation of duration of arrhythmic episode, evaluation of anticoagulation regimen, exclusion of other supraventricular arrhythmias and assessment of the chance of rhythm conversion and persistence of sinus rhythm. Finally, the choice of adequate antiarrhythmic drug (AAD) depends on the presence of structural heart disease and local experience. In patients without structural heart disease, complications occur rarely, hence traditional (propafenone, flecainide) or nonclassical Vaughan-Williams class I (antazoline) or class III (vernakalant, ibutilide or dofetilide) drugs are preferred. The presence of structural heart disease consistent with any left ventricular hypertrophy, heart failure, myocardial ischemia or valvular heart disease confines the choice of AAD to amiodarone. Given the risk of ventricular proarrhythmia of AAD, safety should always prevail over the enticing possibility of rhythm conversion. The present review aims to provide a comprehensible summary of proper qualification for PC, selection of suitable AAD and state-of-the-art periprocedural management of patients with recent-onset AF.

2023-08-12·Journal of molecular and cellular cardiology

Utilizing human induced pluripotent stem cells to study atrial arrhythmias in the short QT syndrome.

Article

作者: Assad Shiti ; Gil Arbil ; Naim Shaheen ; Irit Huber ; Noga Setter ; Lior Gepstein

BACKGROUND:

Among the monogenic inherited causes of atrial fibrillation is the short QT syndrome (SQTS), a rare channelopathy causing atrial and ventricular arrhythmias. One of the limitations in studying the mechanisms and optimizing treatment of SQTS-related atrial arrhythmias has been the lack of relevant human atrial tissues models.

OBJECTIVE:

To generate a unique model to study SQTS-related atrial arrhythmias by combining the use of patient-specific human induced pluripotent stem cells (hiPSCs), atrial-specific differentiation schemes, two-dimensional tissue modeling, optical mapping, and drug testing.

METHODS AND RESULTS:

SQTS (N588K KCNH2 mutation), isogenic-control, and healthy-control hiPSCs were coaxed to differentiate into atrial cardiomyocytes using a retinoic-acid based differentiation protocol. The atrial identity of the cells was confirmed by a distinctive pattern of MLC2v downregulation, connexin 40 upregulation, shorter and triangular-shaped action potentials (APs), and expression of the atrial-specific acetylcholine-sensitive potassium current. In comparison to the healthy- and isogenic control cells, the SQTS-hiPSC atrial cardiomyocytes displayed abbreviated APs and refractory periods along with an augmented rapidly activating delayed-rectifier potassium current (I_Kr). Optical mapping of a hiPSC-based atrial tissue model of the SQTS displayed shortened APD and altered biophysical properties of spiral waves induced in this model, manifested by accelerated spiral-wave frequency and increased rotor curvature. Both AP shortening and arrhythmia irregularities were reversed by quinidine and vernakalant treatment, but not by sotalol.

CONCLUSIONS:

Patient-specific hiPSC-based atrial cellular and tissue models of the SQTS were established, which provide examples on how this type of modeling can shed light on the pathogenesis and pharmacological treatment of inherited atrial arrhythmias.

项与盐酸维那卡兰相关的新闻（医药）

2022-08-29

·BioSpace

Hypertrophic Cardiomyopathy Therapeutics Market is Expected To Reach USD 1.42 Billion By 2027 at a CAGR of 2.1%

According to the current analysis of Reports and Data, the global Hypertrophic Cardiomyopathy Therapeutics Market valued at USD 1.20 Billion in 2019 and is expected to reach USD 1.42 billion by the year 2027, at a CAGR of 2.1%. Hypertrophic cardiomyopathy (HCM) alters the functioning of the heart. Increasing prevalence of cardiovascular disorders, lifestyle habits like smoking and consumption of alcohol, obesity, and growth in the geriatric populations are the factors driving the growth of the market. However, the high-cost expenditure of treatment is restraining the market. According to the report, the World Health Organization (WHO) estimated that 17.9 million people died from cardiovascular diseases in the year 2016, which includes approximately 31% of all global deaths. According to the WHO, in 2016, more than 1.9 billion adults aged 18 years and older were overweight. Regionally, in Africa, the number of overweight children under five has increased by nearly 50% since 2000. Approximately half of the children under five who were overweight or obese in 2018 lived in Asia. The prevalence of obesity among children and adolescents aged 5-19 has risen dramatically. According to Canadian Community Health Survey, in 2018, nearly 63.1% of Canadian adults were either obese or overweight, in which approximately 26.8%, i.e., 7.3 million adults, were obese and another 9.9 million, i.e., 36.3% of Canadian adults were overweight. In 2019 approximately 35% of Americans were obese or overweight in the United States. Access Free sample PDF Copy of the Report (To Understand the Complete Structure of this Report [Summary + TOC]) @ Asia Pacific region is likely to increase the market growth due to factors like an increase in the patient population, lifestyle habits like smoking and consumption of alcohol and, rise in the geriatric population, etc. Further key findings from the report suggest In the year 2019, Correvio Pharma had resubmitted the New Drug Application (NDA) for Brinavess (vernakalant hydrochloride) for the treatment of cardiac arrhythmias to the Food and Drug Administration. But the FDA issued a CRL letter to Correvio Pharma and rejected Brinavess (vernakalant hydrochloride) as it was seen that the drug had prolonged atrial refractoriness and slowed the impulse conduction in a rate-dependent fashion, but the data provided in the application did not provide reassurance of the safety. The NYIT College of Osteopathic Medicine (NYITCOM) researchers, offered a new treatment for patients with beta-blocker intolerance, here T3 (thyroid hormone therapy) was used in the treatment. It is an effective method for managing cardiovascular disorders, and showed better contraction and relaxation of the heart, and was found to be a better treatment for patients. Strokes are one of the causes of hypertrophic cardiomyopathy. In February 2020, the FDA had approved a clinical trial that on Abbott's Amplatzer Amulet, a stroke prevention device it was found to be more beneficial than the new class of blood thinners that are currently used in the treatment. It involves a minimally invasive procedure used for patients with atrial fibrillation. It is an effective non-prescription drug alternative for patients with arterial fibrillation who are at an increased risk for ischemic stroke. Medtronicin January 2020, had announced that it had received the CE Mark for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D).ICDs are used to monitor heart rhythms and supply proper therapy to correct heart rates that are too fast that lead to sudden cardiac arrest. CRT-Ds is a treatment option for some individuals with heart failure; it sends small electrical impulses to the lower chambers of the heart to support them beat in more synchronized patterns and to reduce arrhythmia symptoms. Merck in the year 2019 announced an acquisition of ArQule for arround USD 2.7 billion. This acquisition had strengthened Merck's pipeline it and also included ARQ 531 for the treatment of B-cell malignancies. By Drugs segment, the antiarrhythmic drugs have obtained the largest share of about 36.4% in the year 2019, due to the rise in the incidences of cardiac arrhythmias and also due to the lifestyle factors like smoking and consumption of alcohol On the basis of devices defibrillators accounted for USD 598.3 million for the year 2019. The ongoing pandemic is significantly changing the dynamics of the pharma and healthcare sector. Various countries are facing challenges such as shortage of medicines, vaccines, healthcare devices in hospitals. This is expected to open lucrative growth opportunities for market players in the coming years. For Inquiry Before Buying @ Competitive Landscape: The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market. Top Companies Profiled in the Report: AstraZeneca, Merck, Pfizer, Sanofi, Gilead Sciences, Novartis, Teva Pharmaceutical, Correvio Pharma Industries, Abbot, Lupin limited Browse Full Report Description with Research Methodology, Table of Content and Infographics @ Hypertrophic Cardiomyopathy Therapeutics Market Segmentation: Drugs Outlook (Revenue in Million USD; (2017–2027) Antiarrhythmic Agents Anticoagulants Beta-Adrenergic Blocking Agents Calcium Channel Blockers Others Devices Outlook (Revenue in Million USD; (2017–2027) Defibrillators Pacemakers Other Medical Devices End Use Outlook (Revenue in Million USD; (2017–2027) Hospitals Clinics Others Regional Outlook: North America (U.S., Canada, Mexico) Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe) Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific) Latin America (Brazil, Rest of LATAM) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa) Ask for Customize Research Report @ This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth. Explore More Industry Research by Reports and Data: Aesthetic Medicine Market Size, Share, Trends, By Product (Energy-Based Devices, Implants, Anti-Wrinkle Products), By Application (Surgical, Non-Surgical), End-use (Medical Spas and Beauty Centers), and By Region Forecast to 2030 Download PDF Brochure Surgical Glue Market, By Product Type (Synthetic and Semi-Synthetic, Natural), By Application (Cardiovascular Surgery, Pulmonary Surgery, Others), By End-use (Hospitals, Ambulatory Surgical Centers, Others), and By Region Forecast to 2030 Download PDF Brochure Hernia Mesh Market By Hernia Type (Inguinal Hernia, Incisional Hernia, Femoral Hernia, and Others), By Mesh Type, By Synthetic Structure Type, By Synthetic Product Type, and By End Users And Segment Forecasts, 2020-2028 Download PDF Brochure Anxiety Disorder and Depression Treatment Market By Therapies (Cognitive Behavior Therapy (CBT)), By Drug Class (Antidepressant Drugs, Selective Serotonin Reuptake Inhibitors (SSRIs)), By Devices, By Application, and End-users, And Segment Forecasts To 2028 Download PDF Brochure About Reports and Data Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors. Contact Us: John W Head of Business Development Reports And Data | Web: Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com LinkedIn | Twitter | Blogs Read the innovative blog at Check out our upcoming research report at For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update:

疫苗并购合作

2022-05-31

·丁香园

马长生教授：心房颤动的急诊处理 | OCC 2022

第十六届东方心脏病学会议（OCC 2022）于 2022 年 5 月 25 日～ 5 月 29 日以线上形式举办。在心脏急症论坛中，来自首都医科大学附属安贞医院的马长生教授就「心房颤动的急诊处理」一题进行分享。现梳理重点内容如下。1 急诊房颤增加心血管事件风险急诊房颤就诊率逐年上升急诊患者合并房颤增加死亡及卒中风险：前瞻性队列研究（2007～2011）心梗合并房颤增加死亡率：丹麦国家患者注册库（1997～2009）快房颤伴 TnI 升高可致 MACE 风险增加：回顾性研究（2008～2017）心衰合并房颤死亡风险增加：ACALM 注册研究2 复律时机的选择及其策略频繁复律增加卒中风险：FinCA-4 研究复律期间抗凝不充分增加血栓栓塞风险合并心衰和糖尿病时电复律栓塞风险升高：FinCA 研究未抗凝患者＞ 12 小时复律增加血栓栓塞风险维持窦律 —— 延迟复律不劣于早期复律：RACE 7 ACWAS 研究，非劣效 RCT复律后左心耳功能恢复需要 2～3 周* 复律的「前 3 后 4」原则原因：复律后左心耳电活动恢复，机械活动未恢复，需抗凝。电复律前应用抗心律失常药物（AADs）安全有效：RAFF2 研究，RCT电复律电极板位置不影响转窦率：RAFF2 研究，RCT房颤药物复律指南建议氟卡尼吸入剂快速转复房颤：剂量探索试验药物复律维纳卡兰优于氟卡尼「口袋药」在部分人群中安全有效3 心室率控制策略宽松室率控制不劣于严格室率控制：RACE II 研究合并 HFrEF 时美托洛尔与地尔硫卓可迅速控制心室率4 血流动力学不稳定的房颤定义1）收缩压 < 90 mmHg 并有低灌注的表现：* 精神状态改变：不安、躁动、迟钝；* 皮肤湿冷；* 尿量减少（< 20 mL/h）等。2）肺水肿3）心肌缺血（胸痛和/或有急性缺血的心电图表现）处理紧急电复律 + 尽早启动抗凝高危预激合并房颤可选择急诊消融5 房颤管理进入节律控制时代早期节律控制改善房颤患者预后：EAST-AFNET4 研究房颤治疗导管消融优于 AADs：STOP AF First 研究排版：ly投稿：wangliya1@dxy.cn题图来源：站酷海洛

2010-09-02

·BioSpace

Cardiome Pharma Corp. Gets Nod For Marketing Heart Drug In EU; Receives $30 Million From Merck Sharp & Dohme

VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ:CRME - News) today announced that it has earned a US$30 million milestone payment from its collaboration with Merck (known as MSD outside the United States and Canada), through an affiliate. The milestone was triggered by the recently announced marketing approval for BRINAVESS(TM) (vernakalant (iv)) in the European Union, Iceland and Norway. "European approval and the milestone payment further strengthen Cardiome's financial position, both in the near term and in the long term via royalties from product sales," said Doug Janzen, Chief Executive Officer and President of Cardiome. "The teams at Merck and Cardiome have done an exemplary job in gaining European regulatory approval for BRINAVESS, and Cardiome is now part of a select group of biotechnology companies who have successfully shepherded a molecule from discovery through to product approval." Merck Cardiome Agreement In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and Dohme Corp. (formerly known as Merck & Co., Inc.) with exclusive global rights to vernakalant oral formulation for the maintenance of normal heart rhythm in patients with atrial fibrillation (AF), and provides another Merck affiliate, Merck Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the United States, Canada and Mexico to vernakalant IV formulation for rapid conversion of recent onset AF to sinus rhythm in adults. About Cardiome Pharma Corp. Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at Forward-Looking Statement Disclaimer Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements regarding product revenues following Merck's expected launch of BRINAVESS and other statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may effect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at and the Canadian securities regulatory authorities at Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

合作

100 项与盐酸维那卡兰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06665	盐酸维那卡兰	C01BG11	DB06217

研发状态

适应症	最高研发状态	国家/地区	公司
心房颤动	批准上市	阿拉伯联合酋长国更多	Correvio Pharma Corp. 更多
心房扑动	无进展	美国更多	Astellas Pharma, Inc. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01174160 (CTgov)	临床3期	心房颤动	123	Placebo to vernakalent hydrochloride	顧網艱鏇範繭遞艱範鏇(廠願鹽窪壓憲壓鹽鬱繭) = 範獵衊範衊積餘製齋鑰獵衊糧願餘鬱鏇齋顧糧 (餘範齋淵鹹衊襯衊衊獵, 築鏇餘齋鹽積窪襯簾願 ~ 鹽築鬱積顧積遞襯鹽艱) 更多	-	2015-12-15
NCT00476112 (Pubmed \| Europace)	临床2/3期	心房扑动	60	Vernakalant	蓋網選餘鑰鹽壓醖選窪(觸範顧獵築選夢築顧築) = 顧積憲襯廠膚鏇構壓繭製遞願壓艱壓簾夢蓋窪 (齋範齋顧艱簾製淵衊鏇 )	不佳	2012-06-01
NCT01447862 (Pubmed \| Europace)	临床4期	心房颤动	100	Vernakalant	糧鹽鏇齋構醖範範憲鑰(構願蓋憲顧鏇顧夢網壓) = 蓋醖築衊鹹積夢廠願構醖艱窪遞獵顧淵憲鏇製 (選膚壓鏇艱餘憲鏇選築 ) 更多	积极	2017-02-01
				Ibutilide	糧鹽鏇齋構醖範範憲鑰(構願蓋憲顧鏇顧夢網壓) = 選衊蓋觸網繭糧鹹糧壓醖艱窪遞獵顧淵憲鏇製 (選膚壓鏇艱餘憲鏇選築 ) 更多
ESC2016	N/A	心房颤动	8	AP14145	(窪艱壓衊襯獵齋積艱艱) = 顧襯構壓餘觸選夢繭醖襯遞鬱顧構製鏇膚鏇艱 (餘簾簾憲鹽繭蓋醖獵顧 )	-	2016-08-29
				Vernakalant	(窪艱壓衊襯獵齋積艱艱) = 壓願憲獵餘積築襯構蓋襯遞鬱顧構製鏇膚鏇艱 (餘簾簾憲鹽繭蓋醖獵顧 )
NCT00281554 \| NCT00468767 (ACT I and ACT IV, Pubmed \| Acad Emerg Med)	临床3期	心房颤动	290	Vernakalant	遞憲觸顧構壓獵構範鏇(壓簾膚壓廠壓願鹽網醖) = 鑰築鹽壓製選襯齋顧簾選製積餘網顧鬱鹽艱夢 (選齋願衊糧觸艱積膚窪 )	积极	2010-11-01
NCT01174160 (Pubmed \| Am J Cardiol) 人工标引	临床3期	心房颤动	111	Vernakalant	選鹽鬱淵壓膚窪衊鏇範(餘夢築築積窪糧製膚廠) = 遞選夢鬱餘餘憲遞蓋繭選鬱襯顧鹽鬱製憲簾積 (範窪範膚積鏇蓋顧廠壓 )	积极	2017-02-01
				Placebo	選鹽鬱淵壓膚窪衊鏇範(餘夢築築積窪糧製膚廠) = 範蓋廠壓獵願範膚繭鬱選鬱襯顧鹽鬱製憲簾積 (範窪範膚積鏇蓋顧廠壓 )
NCT00668759 (AVRO, Pubmed \| J Am Coll Cardiol)	临床3期	心房颤动	254	Vernakalant	壓鏇艱淵鹹憲繭窪顧築(壓選糧積壓繭製壓遞鏇) = 獵構膚憲夢製醖積範鏇鹽繭觸網鬱鑰鹽淵鑰壓 (獵鑰艱蓋襯觸製鏇鹽鬱 )	积极	2011-01-18
				Amiodarone	壓鏇艱淵鹹憲繭窪顧築(壓選糧積壓繭製壓遞鏇) = 獵遞簾蓋選鹹觸顧鑰築鹽繭觸網鬱鑰鹽淵鑰壓 (獵鑰艱蓋襯觸製鏇鹽鬱 )
SPECTRUM (ESC2019)	N/A	新发房颤	-	Vernakalant	繭鑰壓淵網齋壓構蓋襯(膚獵糧夢積願構顧廠衊) = 糧鹽窪蓋選網艱糧鹹網積壓衊鏇觸膚衊窪衊壓 (餘選憲範齋憲廠蓋遞繭, 68.1–72.2) 更多	-	2019-09-02
NCT00989001 (ACT V, Pubmed) 人工标引	临床3期	心房颤动	217	vernakalant	壓選鬱鹹壓網衊構衊廠(範壓繭憲網淵遞艱醖選) = 蓋糧壓範襯獵壓積憲壓願餘鹽鹽製製蓋獵蓋網 (醖鹹築醖膚築選構獵觸 )	积极	2016-05-28
				Placebo	壓選鬱鹹壓網衊構衊廠(範壓繭憲網淵遞艱醖選) = 製觸艱積蓋窪範選願鏇願餘鹽鹽製製蓋獵蓋網 (醖鹹築醖膚築選構獵觸 )